TrialBMC infectious diseases2025

A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland.

Juliette Besson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.